Drug Profile
Research programme: CD8 antagonists - MediGene
Alternative Names: YourDexLatest Information Update: 30 Aug 2010
Price :
$50
*
At a glance
- Originator Avidex
- Developer MediGene Ltd
- Class Proteins
- Mechanism of Action CD8 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis; Transplant rejection
Most Recent Events
- 12 Dec 2007 Preclinical trials in Psoriasis in United Kingdom (Parenteral)
- 12 Dec 2007 Preclinical trials in Transplant rejection in United Kingdom (Parenteral)
- 29 Sep 2006 Avidex is acquired by MediGene AG